Central America (Costa Rica, Panama and Guatemala and Dominican Republic) Acute Myeloid Leukemia Market is expected to grow with a CAGR of 5.5% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/central-america-acute-myeloid-leukemia-drugs-market
Central America (Costa Rica, Panama and Guatemala and Dominican Republic) acute myeloid leukemia market have witnessed increased strategic developments owing to a favourable market scenario.
The major players dealing in Central America (Costa Rica, Panama and Guatemala and Dominican Republic) acute myeloid leukemia market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement, new product launches into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance-
- In November 2020, Pfizer Inc. had received approval from the Food and Drug Administration (FDA) for Daurismo. Daurismo, is an oral medication, for treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients, aged above 75 years. The approval received would ensure the process of post marketing approval, addition of a new product in the Oncology portfolio. It would result in growth in revenue and availability in Central American countries.
Pfizer Inc. is the dominating player in the Central America (Costa Rica, Panama and Guatemala and Dominican Republic) acute myeloid leukemia market. The other key players existing in the market includes MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.), AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Novartis AG, Viatris Inc., Bohringer Ingelheim International GmbH, Fresenius Kabi AG, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. among others.
Pfizer Inc.
Pfizer Inc. is headquartered in New York, U.S.and was founded in 1849. The company focuses on providing quality standards, safety, and value in the discovery, development, and manufacturing of healthcare products, including innovative medicines and vaccines. The company is dealing in the business segment such as Pfizer CentreOne, Pfizer BiopharmaceuticalsGroup (Biopharma) in which the market focused segment is Pfizer BiopharmaceuticalsGroup (Biopharma). The company has product categories like internal medicine, inflammation & immunology, oncology, rare disease, vaccines, and anti-infectives and the market-focused category is oncology.
The company is engaged in the continuous development of acute myeloid drugs.
For instance,
- In November 2020, Pfizer Inc. received approval from the Food and Drug Administration (FDA) for Daurismo. Daurismo, is an oral medication, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients, aged over 75 years. The approval received would ensure the process of post-marketing approval, and the addition of a new product to the Oncology portfolio. It would result in growth in revenue and availability in Central American countries.
The company has a wide presence across North America, South America, Europe, Middle East and Africa, and Asia-Pacific. The company also has various subsidiary companies such as Pfizer Animal Health B.V.(Netherlands), Pfizer Asia International B.V.(Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic), and Pfizer Egypt S.A.E.(Egypt), among others.
AbbVie Inc.
AbbVie, Inc. is headquartered in Illinois, U.S. The company was established in 2013. The company focuses on discovering and delivering innovative medicines and products to solve serious health issues. The company has product categories including Immunology, oncology, neuroscience, eye care, virology, and women’s health and the market-focused category is oncology.
The company is engaged in the continuous development of acute myeloid drugs.
For instance,
- In May 2021, AbbVie Inc. had received approval from the European Commission for Venclexta, combined with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults, aged 75 years and above. It is jointly developed by AbbVie Inc. and Genentech, a member of Roche group. Venclexta were made available to patients who can’t undergo intensive chemotherapy. The approval received, had made AbbVie Inc. expand the oncology product line across Europe and Latin America
The company has wide presence across North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The company has various subsidiaries like AbbVie Aviation LLC (U.S.), AbbVie Biopharmaceuticals LLC (U.S.), AbbVie Bioresearch Center Inc. (U.S.), AbbVie Biotech Ventures Inc. (U.S.), and AbbVie Biotherapeutics Inc. (U.S.) among others.
Novartis AG
Novartis AG has its headquarters in Baden-Württemberg, Switzerland and was founded in 1996. The company engages in the development, manufacture, and marketing of healthcare products. The company has business segments such as innovative medicines, sandoz, and corporate in which market-focused segment is innovative medicines. This company has product categories including cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience, and respiratory which the market focused category is cancer.
The company is engaged in the continuous development of acute myeloid drugs.
For instance,
- In September 2017, Novartis AG received approval from the European Union, for Rydapt for treatment of FLT3-mutated acute myeloid leukemia (AML). The approval received would ensure post-marketing approval of Rydapt in Europe and in countries in South America.
The company has a wide presence across North America, Europe, Middle East and Africa. The company also has various subsidiary companies such as Novartis Argentina S.A. (Argentina), Novartis Australia Pty Ltd (Australia), Novartis Austria GmbH (Austria), and Novartis Pharma NV (Belgium) among others.
